New hope for rare liver disease: phase 3 trial launches
NCT ID NCT07499544
First seen Apr 04, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. Participants receive the drug intravenously every two weeks for up to 96 weeks. The goal is to see if the drug can lower the virus level and improve liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China
Conditions
Explore the condition pages connected to this study.